ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO404

Response to Induction Therapy and Treatment Adverse Events in Incident ANCA-Associated Vasculitis (AAV) Patients

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Rutherford, Peter A., Vifor Pharma, Glattbrugg, Switzerland
  • Goette, Dieter Karl, Vifor Pharma, Glattbrugg, Switzerland
  • Stamm, Melinda, Elma Research, London, United Kingdom
  • Liu, Xierong, Elma Research, London, United Kingdom
Background

AAV is a severe systemic vasculitis with a variable clinical presentation and frequent renal involvement. Rapid induction of remission is desirable and therapy is typically a combination of high dose glucocorticoids (GC) with rituximab (RTX) or cyclophosphamide (CYC). Treatment-related adverse events (AEs) are common and contribute to long term organ damage as well as acute morbidity. This retrospective study aimed to document clinical outcomes and AEs in incident AAV patients managed in routine clinical practice.

Methods

929 incident AAV patients from 4 European countries (399 physicians) were diagnosed between 2014-17 and data collected at baseline, 1, 3, 6 and 12 months following commencement of induction therapy was reviewed.

Results

54% of patients had granulomatosis with polyangiitis, and 46% had microscopic polyangiitis; mean age was 56.82 years (SD 14.2) with 53.7% male. Birmingham vasculitis activity score (BVAS) was used in only 12% of cases. Physicians reported 12% patients as mild/localized, 54% as moderate systemic and 34% as severe life threatening AAV. Induction therapy varied with 59% receiving CYC, 24% RTX and 3% a combination of CYC+RTX+GC, whilst 83% received GCs. As BVAS was not used routinely, clinical response was assessed as full (no vasculitis activity and GC taper on track), partial (reduction in vasculitis activity), or no response (no improvement in vasculitis). Response rate varied and AEs were common. Full response at 1 month was associated with good 12-month outcomes (81% full response) whereas partial response at 1 month (56%) was associated with less favorable outcomes (58% full response at 12 months). 6% of incident patients relapsed within the first 12 months.

Conclusion

Response rate to remission induction therapy in AAV is still variable. Early response is associated with a better response rate at 12 months. Infections and treatment-related AEs are common, especially in the first 3 months. New targeted therapy options are needed to improve response rates and reduce burden of therapy.

 1 month3 months6 months12 months
Full Response %18436159
At least one AE %45423530
Infection %27282320
Still receiving GC %82796753
Commenced dialysis %16311

Funding

  • Commercial Support